A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy

E-resources

Peer reviewed

A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy

Tanaka, Toshio; Narazaki, Masashi; Ogata, Atsushi; Kishimoto, Tadamitsu

Seminars in immunology, 02/2014, Volume: 26, Issue: 1

Journal Article

Highlights • Tocilizumab is used as a biologic drug for rheumatoid arthritis, juvenile idiopathic arthritis, and Castleman's disease. • IL-6 blockade strategy will be widely applicable for various refractory inflammatory autoimmune diseases. • The mystery remains as to why IL-6 is persistently expressed in various diseases.

Keep searching

Author

Tanaka, Toshio | Narazaki, Masashi | Ogata, Atsushi | Kishimoto, Tadamitsu

Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.

Year	Impact factor		Edition		Category		Classification
Year	JCR	SNIP	JCR	SNIP	JCR	SNIP	JCR	SNIP

Links to authors' personal bibliographies	Links to information on researchers in the SICRIS system

Source: Personal bibliographies and: SICRIS

Upload image

Shelf entry

Adding material to shelf was successful.

Adding material to shelf failed.

It was not necessary to add the material to the shelf.

Permalink

E-mail

Impact factor

Select the library membership card:

DRS, in which the journal is indexed

Citations

Theme